Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 210-216

  Sazonov, Vasilisa ^a   Beetsch, Joel ^a   Phatak, Hemant ^a   Wentworth, Chuck ^b   Evans, Marc ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Analytic Consulting Solutions   (United States)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular disease; Cerebrovascular disease; Dyslipidemias; High density lipoprotein cholesterol; Hydroxymethylglutaryl CoA reductase inhibitors; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; UNITED KINGDOM;

AGED; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL, HDL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 73449099574     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.07.021     Document Type: Article

References (29)

1. Coronary heart disease: national service framework for coronary heart disease-modern standards and service models. Available at http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Accessed July 19, 2005. ed. 2000.
2. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
3. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104 (2001) 2376-2383
4. Clarke R., Emberson J.R., Parish S., et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med 167 (2007) 1373-1378
5. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
6. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85 (1992) 37-45
7. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
8. Walley T., and Mantgani A. The UK General Practice Research Database. Lancet 350 (1997) 1097-1099
9. Jick S.S., Kaye J.A., Vasilakis-Scaramozza C., et al. Validity of the General Practice Research Database. Pharmacotherapy 23 (2003) 686-689
10. Wattanasuwan N., Khan I.A., Gowda R.M., Vasaveda B.C., and Sacchi T.J. Effect of acute myocardial infarction on cholesterol ratios. Chest 120 (2001) 1196-1199
11. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Consulted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prevent Rehab 14 suppl. 2 (2007) S1-113
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
13. Van Ganse E., Laforest L., Burke T., Phatak H., and Souchet T. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 29 (2007) 1671-1681
14. Bruckert E., Baccara-Dinet M., and Eschwege E. Low HDL-cholesterol is common in European type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 24 (2007) 388-391
15. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
16. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
17. de Goma E.M., Leeper N.J., and Heidenreich P.A. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 51 (2008) 49-55
18. Amarenco P., Labreuche J., and Touboul P.-J. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196 (2008) 489-496
19. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., and Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008) 724-730
20. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
21. Tenkanen L., Manttari M., Kovanen P.T., et al. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 (2006) 743-748
22. Haim M., Benderly M., Brunner D., et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 100 (1999) 475-482
23. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
24. Rizos E., and Mikhailidis D.P. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol 82 (2002) 199-207
25. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
26. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness. Curr Med Res Opin 22 (2006) 2243-2250
27. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
28. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
29. Ericsson C.G., Nilsson J., Grip L., et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 80 (1997) 1125-1129